Paysign, Inc. (PAYS)

NCM – Real vaqt narxi. Valyuta: USD

6.65

-0.05 (-0.75%)

Yopilishda: May 12, 2026, 4:00 PM EDT

6.30

-0.35 (-5.19%)

Bozor oldidan: May 13, 2026, 7:21 AM EDT

12.05.2026

Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.

15.04.2026

Paysign to Host First Quarter 2026 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host First Quarter 2026 Earnings Call.

09.04.2026

Paysign: The Market Is Finally Repricing A Pharma Margin Story

Paysign is evolving beyond a niche prepaid card processor, with patient affordability now driving higher-margin growth. 2025 results highlight a 40.5% revenue increase to $82M, with pharma revenue surging to $33.9M and gross margin expanding to 59.4%. PAYS trades above peer sales multiples, reflecting its shift to a high-value workflow business, while price-to-cash flow remains attractive if cash conversion holds.

31.03.2026

Paysign Is On A Roll

Paysign remains a buy, supported by strong performance in both Plasma Centers and hypergrowth in Patient Affordability. PAYS's Plasma Center segment holds a 50% market share, adding 115 new centers in FY25, despite revenue per center declining due to plasma surplus. That surplus can disappear, and the Plasma segment can benefit from the BECS, generating high-margin SaaS subscription revenue.

25.03.2026

Why Paysign Stock Is Skyrocketing Today

Paysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations. The company's forward guidance is spurring huge gains for the stock.

25.03.2026

Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript

24.03.2026

Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.

24.03.2026

Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results.

07.01.2026

Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Announces 2025 Performance Analysis of Patient Affordability Solutions.

12.11.2025

Paysign, Inc. Reports Third Quarter 2025 Financial Results

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Third Quarter 2025 Financial Results.

Paysign, Inc. (PAYS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Paysign, Inc. (PAYS)

Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

Paysign to Host First Quarter 2026 Earnings Call